keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant breast cancer therapy

keyword
https://www.readbyqxmd.com/read/27912846/new-insights-and-evolving-role-of-pegylated-liposomal-doxorubicin-in-cancer-therapy
#1
REVIEW
Alberto A Gabizon, Yogita Patil, Ninh M La-Beck
We herein review various pharmacological and clinical aspects of pegylated liposomal doxorubicin (PLD), the first nanomedicine to be approved for cancer therapy, and discuss the gap between its potent antitumor activity in preclinical studies and its comparatively modest achievements in clinical studies and limited use in clinical practice. PLD is a complex formulation of doxorubicin based on pharmaceutical nanotechnology with unique pharmacokinetic and pharmacodynamic properties. Its long circulation time with stable retention of the payload and its accumulation in tumors with high vascular permeability both result in important advantages over conventional chemotherapy...
November 2016: Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
https://www.readbyqxmd.com/read/27903675/a-pam50-based-chemo-endocrine-score-for-hormone-receptor-positive-breast-cancer-with-an-intermediate-risk-of-relapse
#2
Aleix Prat, Ana Lluch, Arran K Turnbull, Anita K Dunbier, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Angels Arcusa, Ignacio Chacón, Pedro Sánchez-Rovira, Arrate Plazaola, Montse Muñoz, Laia Paré, Joel S Parker, Nuria Ribelles, Begona Jimenez, Abdul Aziz Bin Aiderus, Rosalía Caballero, Barbara Adamo, Mitch Dowsett, Eva M Carrasco, Miguel Martín, J Michael Dixon, Charles M Perou, Emilio Alba
PURPOSE: Hormone receptor-positive (HR+) breast cancer is clinically and biologically heterogeneous and subgroups with different prognostic and treatment sensitivities need to be identified. EXPERIMENTAL DESIGN: Research-based PAM50 subtyping and expression of additional genes was performed on 63 patients with HR+/HER2- disease randomized to neoadjuvant multi-agent chemotherapy versus endocrine therapy in a phase II trial. The biology associated with treatment response was used to derive a PAM50-based Chemo-Endocrine Score (CES)...
November 30, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27903276/accurate-prediction-of-response-to-endocrine-therapy-in-breast-cancer-patients-current-and-future-biomarkers
#3
REVIEW
Cigdem Selli, J Michael Dixon, Andrew H Sims
Approximately 70% of patients have breast cancers that are oestrogen receptor alpha positive (ER+) and are therefore candidates for endocrine treatment. Many of these patients relapse in the years during or following completion of adjuvant endocrine therapy. Thus, many ER+ cancers have primary resistance or develop resistance to endocrine therapy during treatment. Recent improvements in our understanding of how tumours evolve during treatment with endocrine agents have identified both changes in gene expression and mutational profiles, in the primary cancer as well as in circulating tumour cells...
December 1, 2016: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/27889596/using-ultrasound-and-palpation-for-predicting-axillary-lymph-node-status-following-neoadjuvant-chemotherapy-results-from-the-multi-center-sentina-trial
#4
Lukas Schwentner, Gisela Helms, Valentina Nekljudova, Beyhan Ataseven, Ingo Bauerfeind, Nina Ditsch, Tanja Fehm, Barbara Fleige, Maik Hauschild, J Heil, Sherko Kümmel, Anette Lebeau, Sabine Schmatloch, Peter Schrenk, Anette Staebler, Sibylle Loibl, Michael Untch, Gunter Von Minckwitz, Cornelia Liedtke, Thorsten Kühn
BACKGROUND: With the growing importance of neoadjuvant systemic therapy (NST) the assessment of post neoadjuvant axillary status is of increasing importance especially in patients who presented initially with suspicious nodes (cN1). This study aims to investigate the predictive value of palpation and axillary ultrasound of formerly cN1 patients following NST. PATIENTS AND METHODS: The SENTINA trial (SENTinel NeoAdjuvant) is a 4-arm prospective multicenter study designed to evaluate the role of sentinel node biopsy (SLNB) in the context of neoadjuvant systemic treatment (NST) of breast cancer patients...
November 24, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27889595/is-there-a-role-for-salvage-radiotherapy-in-locally-advanced-breast-cancer-refractory-to-neoadjuvant-chemotherapy
#5
R C Coelho, F M L Da Silva, I M L Do Carmo, B V Bonaccorsi, S M Hahn, L D Faroni
INTRODUCTION: Locally advanced breast cancer (LABC) is a major problem, especially in developing countries. The standard treatment for LABC is neoadjuvant chemotherapy, with or without anti-Her2 therapy, followed by surgery, radiotherapy, and adjuvant systemic treatment if appropriate. However, there are few data in the literature addressing alternatives when neoadjuvant chemotherapy fails to reduce the tumour for surgery. MATERIALS AND METHODS: We conducted a retrospective study including all patients who had non-metastatic LABC treated with neoadjuvant chemotherapy and who were not eligible for surgical resection; these patients were submitted to salvage radiotherapy (RTX) between January 2000 and December 2012 at the Brazilian National Cancer Institute...
November 24, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27885439/weekly-paclitaxel-plus-carboplatin-with-or-without-trastuzumab-as-neoadjuvant-chemotherapy-for-her2-positive-breast-cancer-loss-of-her2-amplification-and-its-impact-on-response-and-prognosis
#6
Ruo-Xi Wang, Sheng Chen, Xi Jin, Can-Ming Chen, Zhi-Ming Shao
PURPOSE: Neoadjuvant chemotherapy (NCT) plus anti-HER2 agents are the standard of care for locally advanced HER2-positive breast cancer. The aim of this study was to evaluate the prevalence and prognostic impact of HER2 loss in patients with HER2-positive disease treated with neoadjuvant therapy with or without trastuzumab. METHODS: 549 consecutive HER2-positive patients were included in this study. 379 patients were treated with paclitaxel, carboplatin, and trastuzumab (PCH cohort) and 170 were treated with paclitaxel and carboplatin only (PC cohort)...
November 24, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27885165/neoadjuvant-chemotherapy-in-breast-cancers
#7
REVIEW
Shahla Masood
With advances in science and technology, there are more innovations in the approach to management of patients with breast cancer. Neoadjuvant chemotherapy that is designed to be used prior to surgical removal of a tumor has received significant attention. Currently, neoadjuvant chemotherapy is offered to patients with locally advanced breast cancer and also those breast cancer patients who may benefit from size reduction before conservation therapy. There is now sufficient evidence that if neoadjuvant chemotherapy leads to complete pathologic response, the patient will enjoy a better outcome...
September 2016: Women's Health
https://www.readbyqxmd.com/read/27882700/effects-of-lapatinib-or-trastuzumab-alone-and-in-combination-in-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-a-meta-analysis-of-randomized-controlled-trials
#8
Yong Xin, Wen Wen Guo, Qian Huang, Pei Zhang, Long-Zhen Zhang, Guan Jiang, Ye Tian
This meta-analysis compared the efficiency and safety of lapatinib and trastuzumab, alone or in combination, administered with neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. For dichotomous variables, the relative risk ratio (RR) and 95% confidence interval (CI) were used to investigate outcome measures: pathological complete response (pCR), neutropenia, diarrhea, dermatologic toxicity, and congestive heart failure (CHF). Eight randomized controlled trials of 2350 participants (837 receiving lapatinib, 913 trastuzumab, and 555 combination therapy) were selected to compare the efficiency and safety of lapatinib to trastuzumab...
November 23, 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27877006/early-prediction-of-pathological-outcomes-to-neoadjuvant-chemotherapy-in-breast-cancer-patients-using-automated-breast-ultrasound
#9
Xinguang Wang, Ling Huo, Yingjian He, Zhaoqing Fan, Tianfeng Wang, Yuntao Xie, Jinfeng Li, Tao Ouyang
OBJECTIVE: Early assessment of response to neoadjuvant chemotherapy (NAC) for breast cancer allows therapy to be individualized. The optimal assessment method has not been established. We investigated the accuracy of automated breast ultrasound (ABUS) to predict pathological outcomes after NAC. METHODS: A total of 290 breast cancer patients were eligible for this study. Tumor response after 2 cycles of chemotherapy was assessed using the product change of two largest perpendicular diameters (PC) or the longest diameter change (LDC)...
October 2016: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/27875106/neoadjuvant-systemic-therapy-in-breast-cancer-association-of-contrast-enhanced-mr-imaging-findings-diffusion-weighted-imaging-findings-and-tumor-subtype-with-tumor-response
#10
Gorane Santamaría, Xavier Bargalló, Pedro Luis Fernández, Blanca Farrús, Xavier Caparrós, Martin Velasco
Purpose To investigate the performance of tumor subtype and various magnetic resonance (MR) imaging parameters in the assessment of tumor response to neoadjuvant systemic therapy (NST) in patients with breast cancer and to outline a model of pathologic response, considering pathologic complete response (pCR) as the complete absence of any residual invasive cancer or ductal carcinoma in situ (DCIS). Materials and Methods This was an institutional review board-approved retrospective study, with waiver of the need to obtain informed consent...
November 22, 2016: Radiology
https://www.readbyqxmd.com/read/27866067/escalating-and-de-escalating-treatment-in-her2-positive-early-breast-cancer
#11
REVIEW
Heikki Joensuu
The current standard adjuvant systemic treatment of early HER2-positive breast cancer consists of chemotherapy plus 12months of trastuzumab, with or without endocrine therapy. Several trials have investigated modifications of the standard treatment that are shorter and less resource-demanding (de-escalation) or regimens that aim at dual HER2 inhibition or include longer than 12months of HER2-targeted treatment (escalation). Seven randomized trials investigate shorter than 12months of trastuzumab treatment duration...
November 10, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27865536/breast-cancer
#12
REVIEW
Nadia Harbeck, Michael Gnant
Breast cancer is one of the three most common cancers worldwide. Early breast cancer is considered potentially curable. Therapy has progressed substantially over the past years with a reduction in therapy intensity, both for locoregional and systemic therapy; avoiding overtreatment but also undertreatment has become a major focus. Therapy concepts follow a curative intent and need to be decided in a multidisciplinary setting, taking molecular subtype and locoregional tumour load into account. Primary conventional surgery is not the optimal choice for all patients any more...
November 16, 2016: Lancet
https://www.readbyqxmd.com/read/27858093/targeted-intraoperative-radiotherapy-tumour-bed-boost-during-breast-conserving-surgery-after-neoadjuvant-chemotherapy
#13
Hans-Christian Kolberg, Gyoergy Loevey, Leyla Akpolat-Basci, Miltiades Stephanou, Peter A Fasching, Michael Untch, Cornelia Liedtke, Max Bulsara, Jayant S Vaidya
INTRODUCTION: The use of targeted intraoperative radiotherapy (TARGIT-IORT) as a tumour bed boost during breast-conserving surgery (BCS) for breast cancer has been reported since 1998. We present its use in patients undergoing breast conservation following neoadjuvant therapy (NACT). METHOD: In this retrospective study involving 116 patients after NACT we compared outcomes of 61 patients who received a tumour bed boost with IORT during lumpectomy versus 55 patients treated in the previous 13 months with external (EBRT) boost...
November 17, 2016: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/27856630/a-prospective-clinical-trial-of-18f-fluciclovine-pet-ct-neoadjuvant-therapy-response-in-invasive-ductal-and-invasive-lobular-breast-cancers
#14
Gary A Ulaner, Debra Goldman, Adriana Corben, Serge Lyashchenko, Mithat Gonen, Jason Lewis, Maura Dickler
: Fluorine-18-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid ((18)F-Fluciclovine) is a leucine analog radiotracer that depicts amino acid transport into cells. (18)F-Fluciclovine PET/CT visualizes malignancy including prostate cancer, invasive ductal breast cancer (IDC) and invasive lobular breast cancers (ILC). It has not been shown whether changes in (18)F-Fluciclovine avidity reflect changes in tumor burden resulting from treatment. This prospective clinical trial evaluates changes in (18)F-Fluciclovine-avidity compared to breast cancer therapy response, as determined by residual tumor burden on pathology...
November 17, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27856629/functional-estrogen-receptor-imaging-prior-to-neoadjuvant-therapy-for-primary-breast-cancer
#15
Amy M Fowler, Hannah M Linden
No abstract text is available yet for this article.
November 17, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27853985/a-definition-for-aggressive-disease-in-patients-with-her-2-negative-metastatic-breast-cancer-an-expert-consensus-of-the-spanish-society-of-medical-oncology-seom
#16
REVIEW
A González, A Lluch, E Aba, J Albanell, A Antón, I Álvarez, F Ayala, A Barnadas, L Calvo, E Ciruelos, J Cortés, J de la Haba, J M López-Vega, E Martínez, M Muñoz, I Peláez, A Redondo, Á Rodríguez, C A Rodríguez, A Ruíz, A Llombart
PURPOSE: To converge on an expert opinion to define aggressive disease in patients with HER2-negative mBC using a modified Delphi methodology. METHODS: A panel of 21 breast cancer experts from the Spanish Society of Medical Oncology agreed upon a survey which comprised 47 questions that were grouped into three sections: relevance for defining aggressive disease, aggressive disease criteria and therapeutic goals. Answers were rated using a 9-point Likert scale of relevance or agreement...
November 16, 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27848968/in-silico-pathway-activation-network-decomposition-analysis-ipanda-as-a-method-for-biomarker-development
#17
Ivan V Ozerov, Ksenia V Lezhnina, Evgeny Izumchenko, Artem V Artemov, Sergey Medintsev, Quentin Vanhaelen, Alexander Aliper, Jan Vijg, Andreyan N Osipov, Ivan Labat, Michael D West, Anton Buzdin, Charles R Cantor, Yuri Nikolsky, Nikolay Borisov, Irina Irincheeva, Edward Khokhlovich, David Sidransky, Miguel Luiz Camargo, Alex Zhavoronkov
Signalling pathway activation analysis is a powerful approach for extracting biologically relevant features from large-scale transcriptomic and proteomic data. However, modern pathway-based methods often fail to provide stable pathway signatures of a specific phenotype or reliable disease biomarkers. In the present study, we introduce the in silico Pathway Activation Network Decomposition Analysis (iPANDA) as a scalable robust method for biomarker identification using gene expression data. The iPANDA method combines precalculated gene coexpression data with gene importance factors based on the degree of differential gene expression and pathway topology decomposition for obtaining pathway activation scores...
November 16, 2016: Nature Communications
https://www.readbyqxmd.com/read/27842679/routine-use-of-standard-breast-mri-compared-to-axillary-ultrasound-for-differentiating-between-no-limited-and-advanced-axillary-nodal-disease-in-newly-diagnosed-breast-cancer-patients
#18
T J A van Nijnatten, E H Ploumen, R J Schipper, B Goorts, E H Andriessen, S Vanwetswinkel, M Schavemaker, P Nelemans, B de Vries, R G H Beets-Tan, M L Smidt, M B I Lobbes
OBJECTIVES: To compare standard breast MRI to dedicated axillary ultrasound (with or without tissue sampling) for differentiating between no, limited and advanced axillary nodal disease in breast cancer patients. METHODS: All patients who underwent breast MRI and dedicated axillary ultrasound between 2009 and 2014 were eligible. Exclusion criteria were recurrent disease, neoadjuvant systemic therapy and not receiving completion axillary lymph node dissection after positive sentinel lymph node biopsy (SLNB)...
December 2016: European Journal of Radiology
https://www.readbyqxmd.com/read/27829284/professor-charles-e-geyer-neoadjuvant-therapy-is-becoming-standard-of-care-for-her2-breast-cancer
#19
Lucille L Ye
No abstract text is available yet for this article.
October 2016: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/27826664/anti-her2-cd4-t-helper-type-1-immune-response-is-superior-to-breast-mri-for-assessing-response-to-neoadjuvant-therapy-in-patients-with-her2-positive-breast-cancer
#20
Lucy M De La Cruz, Elizabeth S McDonald, R Mick, Jashodeep Datta, Nadia F Nocera, Shuwen Xu, Carla S Fisher, Brian J Czerniecki
BACKGROUND: In human epidermal growth factor 2-positive breast cancer (HER2(+)BC), neoadjuvant chemotherapy and anti-HER2-targeted therapy (nCT) achieves a complete pathologic response (pCR) in 40-67% of patients. Posttreatment magnetic resonance imaging (pMRI) is considered the gold standard, with high specificity but lower sensitivity for assessing response. The authors previously determined that anti-HER2Th1 immune response is associated with pathologic response after nCT in HER2(+)BC patients...
November 8, 2016: Annals of Surgical Oncology
keyword
keyword
74676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"